Phaseline

Companies › Allarity Therapeutics

Allarity Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
2X-121
Poly [ADP-ribose] polymerase-1 inhibitor; Poly [ADP-ribose] polymerase 2 inhibitor; Tankyrase 1/2 inhibitor
PARP1, PARP2, TNKS2, TNKSPhase 2Advanced Ovarian CancerMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT038788492X-121Phase 2Advanced Ovarian CancerOncologyMar 2027

From the company's SEC filings

Cash of $17m on 2026-06-30; operating cash outflow about $14m a year; runway about 14 months at that burn, to Sep 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

PARP1 (1) PARP2 (1) TNKS2 (1) TNKS (1)

Companies with the same targets

AstraZeneca Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) GSK Eikon Therapeutics BeiGene Impact Therapeutics pharmaand Boryung Pharmaceutical

Companies built like this

VIVUS CNS Pharmaceuticals Impact Therapeutics Acrivon Therapeutics Dogwood Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.